Bleakley Financial Group’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Bleakley Financial Group's IBRX Position: Q3 2026 in Review
Bleakley Financial Group increased its ImmunityBio (IBRX) stake by 15% in Q3 2026, buying an estimated $156K and bringing the position to 148,942 shares worth $1.41M. The position accounts for 0.02% of the portfolio, ranked #662.
Bleakley Financial Group first reported a position in IBRX in Q1 2024 and has held it in 7 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Bleakley Financial Group held 148,942 shares of ImmunityBio worth $1.41M as of Q3 2026.
- Bleakley Financial Group bought 19,561 ImmunityBio shares in Q3 2026, an estimated $156K.
- ImmunityBio made up 0.02% of Bleakley Financial Group's portfolio in Q3 2026, its #662 holding.
- Bleakley Financial Group first reported a position in ImmunityBio in Q1 2024 and has held it in 7 quarters since.
- 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Bleakley Financial Group's 13F filing for Q3 2026, filed 13 Nov 2026.